ReviewWorld journal of gastroenterology2015
Cirrhotic cardiomyopathy.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04050683 (Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt), which is not on this map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.
- Liver cirrhosis and left ventricle diastolic dysfunction: Systematic review.World journal of gastroenterology · 2019Pooled it
- Heart-Liver Interactions: Pathophysiology and Diagnosis of Hypoxic Hepatitis, Congestive Hepatopathy, and Cirrhotic Cardiomyopathy.Diagnostics (Basel, Switzerland) · 2026Review
- Regional Anaesthesia Techniques in Liver and Kidney Transplantation: A Narrative Review in Donors and Recipients.Turkish journal of anaesthesiology and reanimation · 2026Article
- Study of Cardiovascular Dysfunction in Cirrhosis and Its Correlation With Severity at a Tertiary Care Hospital.Cureus · 2026Article
- Association of NT-proBNP and sST2 with Diastolic Dysfunction in Cirrhotic Patients and Its Therapeutic Implications.International journal of molecular sciences · 2025Article
- Early Atropine Protocol Enhances Dobutamine Stress Echocardiography in End-Stage Liver Disease: A Practical Cardiac Risk Stratification Tool Before Liver Transplantation.Annals of transplantation · 2025Article
- Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.Heart failure reviews · 2025Review
- Joint Group and Multi Institutional Position Opinion: Cirrhotic Cardiomyopathy-From Fundamentals to Applied Tactics.Medicina (Kaunas, Lithuania) · 2024Review
- Implication of Hypotension in the Pathogenesis of Cognitive Impairment and Brain Injury in Chronic Liver Disease.Neurochemical research · 2024Review
- [Cirrhotic cardiomyopathy – Clinically fact or academic curiosity? Review: Part 1: definition, epidemiology, pathology and clinical manifestations]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2024Article
- Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress.Frontiers in cardiovascular medicine · 2024Review
- Markers of cardiac injury in patients with liver cirrhosis.Croatian medical journal · 2023Review
- Corrected QT interval in cirrhosis: A systematic review and meta-analysis.World journal of hepatology · 2023Article
- Myocardial injury is a risk factor for 6-week mortality in liver cirrhosis associated esophagogastric variceal bleeding.Scientific reports · 2023Article
- Is Cirrhotic Cardiomyopathy Related to Cirrhosis Severity?Rambam Maimonides medical journal · 2023Article
- Hepatic Ischemia/Reperfusion Injury After Liver Transplantation Is Not Associated with Early Impairment of Left Ventricular Ejection Fraction.Annals of transplantation · 2022Article
- Clinical and diagnostic characteristics of the development of hepatocardial syndrome in black and white cows in the early lactation period.Veterinary world · 2022Article
- Chronotropic incompetence in end-stage liver disease.PloS one · 2022Article
- What's New in Cirrhotic Cardiomyopathy?-Review Article.Journal of personalized medicine · 2021Review
- Ability of dynamic preload indices to predict fluid responsiveness in a high femoral-to-radial arterial pressure gradient: a retrospective study.Anesthesia and pain medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the course of cirrhosis, there is a progressive deterioration of cardiac function manifested by the disappearance of the hyperdynamic circulation due to a failure in heart function with decreased cardiac output. This is due to a deterioration in inotropic and chronotropic function which takes place in parallel with a diastolic dysfunction and cardiac hypertrophy in the absence of other known cardiac disease. Other findings of this specific cardiomyopathy include impaired contractile responsiveness to stress stimuli and electrophysiological abnormalities with prolonged QT interval. The pathogenic mechanisms of cirrhotic cardiomyopathy include impairment of the b-adrenergic receptor signalling, abnormal cardiomyocyte membrane lipid composition and biophysical properties, ion channel defects and overactivity of humoral cardiodepressant factors. Cirrhotic cardiomyopathy may be difficult to determine due to the lack of a specific diagnosis test. However, an echocardiogram allows the detection of the diastolic dysfunction and the E/e' ratio may be used in the follow-up progression of the illness. Cirrhotic cardiomyopathy plays an important role in the pathogenesis of the impairment of effective arterial blood volume and correlates with the degree of liver failure. A clinical consequence of cardiac dysfunction is an inadequate cardiac response in the setting of vascular stress that may result in renal hypoperfusion leading to renal failure. The prognosis is difficult to establish but the severity of diastolic dysfunction may be a marker of mortality risk. Treatment is non-specific and liver transplantation may normalize the cardiac function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.